Phase 0 4 trials
Phase 0
NCT05289648 May 2024 → Oct 2025 endometrial cancer , serous adenocarcinoma Sir Mortimer B. Davis - Jewish General Hospital
Withdrawn
No outcome recorded
Phase 0
NCT05406700 May 2023 → Jul 2026 overdue low grade glioma , malignant glioma Massachusetts General Hospital
Active not recruiting
No outcome recorded
Phase 0
NCT05238831 Jan 2023 → May 2026 female breast carcinoma , ovarian carcinoma , pancreatic ductal adenocarcinoma , pancreatic large cell neuroendocrine carcinoma +2 OHSU Knight Cancer Institute
Withdrawn
No outcome recorded
Phase 0
NCT05076513 Oct 2021 → Mar 2024 overdue brain glioblastoma Nader Sanai
Active not recruiting
No outcome recorded
Phase 1 40 trials
Phase 1
NCT06161493 Jan 2024 → Dec 2026 ovarian cancer Haider Mahdi
Withdrawn
No outcome recorded
Phase 1
NCT05666349 Oct 2023 glioblastoma University College, London
Withdrawn
No outcome recorded
Phase 1
NCT05694715 May 2023 → Jan 2028 expected ATM-related cancer predisposition , BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , PALB2-related cancer predisposition +1 University of California, San Francisco
Recruiting
No outcome recorded
Phase 1
NCT04149145 May 2023 → May 2024 ovarian carcinoma University of Alabama at Birmingham
Withdrawn
No outcome recorded
Phase 1
NCT04926324 Jul 2022 → Nov 2024 rectal cancer University of Iowa
Terminated
No outcome recorded
Phase 1
NCT04673448 Oct 2021 → Dec 2025 overdue fallopian tube carcinoma , female breast carcinoma , hereditary breast carcinoma , hereditary neoplastic syndrome +4 University of Washington
Active not recruiting
No outcome recorded
Phase 1
NCT04991480 Sep 2021 → Dec 2025 breast cancer , metastatic malignant neoplasm Artios Pharma Ltd
Completed
No outcome recorded
Phase 1
NCT03944902 Sep 2021 → Jan 2022 ovarian cancer University of Alabama at Birmingham
Terminated
No outcome recorded
Phase 1
NCT04481113 Jun 2021 → Oct 2023 female breast carcinoma , hormone receptor-positive breast cancer , invasive breast carcinoma OHSU Knight Cancer Institute
Completed
No outcome recorded
Phase 1
NCT04764084 Apr → Nov 2021 Her2-receptor negative breast cancer , cholangiocarcinoma , gastric adenocarcinoma , malignant pancreatic neoplasm Peking University Cancer Hospital & Institute
Unknown
No outcome recorded
Phase 1
NCT04762901 Apr 2021 → Jan 2026 breast cancer Wake Forest University Health Sciences
Withdrawn
No outcome recorded
Phase 1
NCT04577833 Nov 2020 → Oct 2021 overdue prostate neoplasm Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1
NCT04544995 Oct 2020 → Apr 2025 neoplasm GlaxoSmithKline
Terminated
No outcome recorded
Phase 1
NCT04502602 Aug 2020 → Oct 2024 overdue ovarian cancer Virginia Commonwealth University
Active not recruiting
No outcome recorded
Phase 1
NCT04235101 Jun 2020 → Apr 2023 cancer Byondis B.V.
Completed
No outcome recorded
Phase 1
NCT04267939 Feb 2020 → Dec 2023 ovarian cancer Bayer
Terminated
No outcome recorded
Phase 1
NCT04178460 Feb 2020 → Mar 2022 biliary tract cancer , endometrial carcinoma , gastric cancer , triple-negative breast carcinoma Zai Lab (Shanghai) Co., Ltd.
Terminated
No outcome recorded
Phase 1
NCT04170153 Dec 2019 → Jul 2026 overdue cancer of unknown primary site EMD Serono Research & Development Institute, Inc.
Active not recruiting
No outcome recorded
Phase 1
NCT03945721 Jul 2019 → Dec 2026 expected triple-negative breast carcinoma Massachusetts General Hospital
Active not recruiting
No outcome recorded
Phase 1
NCT03891615 Jun 2019 → Apr 2022 lung cancer Massachusetts General Hospital
Unknown
No outcome recorded
Phase 1
NCT03586661 Apr 2019 → Jun 2026 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , endometrium adenocarcinoma , fallopian tube carcinoma +2 M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT03895788 Jan → Dec 2019 ovarian cancer Hunan Cancer Hospital
Unknown
No outcome recorded
Phase 1
NCT03695380 Jan 2019 → Jul 2023 ovarian cancer Hoffmann-La Roche
Completed
No outcome recorded
Phase 1
NCT03329937 Apr 2018 → Jan 2020 breast cancer Tesaro, Inc.
Completed
No outcome recorded
Phase 1
NCT03497429 Apr 2018 → Feb 2020 cancer Takeda
Completed
No outcome recorded
Phase 1
NCT03359850 Feb 2018 → Sep 2019 ovarian neoplasm Tesaro, Inc.
Completed
No outcome recorded
Phase 1
NCT03551171 Dec 2017 → May 2018 ovarian cancer Zai Lab (Shanghai) Co., Ltd.
Completed
No outcome recorded
Phase 1
NCT03209401 Oct 2017 → Oct 2023 cancer Georgetown University
Terminated
No outcome recorded
Phase 1
NCT03307785 Oct 2017 → Feb 2020 metastatic malignant neoplasm , non-small cell lung carcinoma Tesaro, Inc.
Completed
No outcome recorded
Phase 1
NCT03076203 Sep 2017 → Jan 2020 hormone-resistant prostate carcinoma , metastatic carcinoma in the bone , prostate adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Completed
No outcome recorded
Phase 1
NCT03154281 Jul 2017 → Apr 2021 breast cancer , ovarian cancer Avera McKennan Hospital & University Health Center
Completed
No outcome recorded
Phase 1
NCT02924766 Oct 2016 → Jul 2019 prostate cancer Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 1
NCT02500901 Mar → May 2016 metastatic prostate carcinoma Paul Mathew, MD
Terminated
No outcome recorded
Phase 1
NCT02476552 Feb → Dec 2015 cancer Tesaro, Inc.
Completed
No outcome recorded
Phase 1
NCT02044120 May 2014 → Jan 2021 Ewing sarcoma Sarcoma Alliance for Research through Collaboration
Completed
No outcome recorded
Phase 1
NCT01294735 Feb 2011 → Apr 2012 glioblastoma , melanoma Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 1
NCT01226901 Nov 2010 → Feb 2011 neoplasm Merck Sharp & Dohme LLC
Terminated
No outcome recorded
Phase 1
NCT01227941 Nov 2010 → Sep 2011 ovarian cancer Tesaro, Inc.
Terminated
No outcome recorded
Phase 1
NCT01110603 Jul 2010 → Jul 2011 —
Tesaro, Inc.
Terminated
No outcome recorded
Phase 1
NCT00749502 Sep 2008 → Sep 2011 B-cell chronic lymphocytic leukemia , T-cell prolymphocytic leukemia , cancer Tesaro, Inc.
Completed
No outcome recorded
Show 30 more trials Phase 1/2 22 trials
Phase 1/2
NCT06682780 Sep 2025 → Dec 2028 expected neoplasm LaNova Medicines Limited
Recruiting
No outcome recorded
Phase 1/2
NCT06953323 Jul 2025 → Jun 2029 expected neoplasm Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Recruiting
No outcome recorded
Phase 1/2
NCT05672095 Apr 2025 → Nov 2026 fallopian tube carcinoma , ovarian carcinoma , primary peritoneal carcinoma City of Hope Medical Center
Withdrawn
No outcome recorded
Phase 1/2
NCT06329830 Oct 2024 → Oct 2026 castration-resistant prostate carcinoma , metastatic prostate carcinoma Baptist Health South Florida
Withdrawn
No outcome recorded
Phase 1/2
NCT06594679 Sep 2024 → Mar 2027 expected ovarian cancer Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting
No outcome recorded
Phase 1/2
NCT06258018 Sep 2024 → Dec 2026 expected malignant glioma Armando Santoro, MD
Not yet recruiting
No outcome recorded
Phase 1/2
NCT05784012 Nov 2023 → Mar 2027 expected head and neck squamous cell carcinoma Spanish Head And Neck Cancer Cooperative Group
Active not recruiting
No outcome recorded
Phase 1/2
NCT06077877 Oct 2023 → Jun 2026 overdue neoplasm GlaxoSmithKline
Active not recruiting
No outcome recorded
Phase 1/2
NCT05519670 Mar 2023 → Sep 2027 expected breast cancer Institut Paoli-Calmettes
Not yet recruiting
No outcome recorded
Phase 1/2
NCT05198804 Jan 2022 → Oct 2025 fallopian tube cancer , ovarian cancer , primary peritoneal carcinoma K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Completed
No outcome recorded
Phase 1/2
NCT04972110 Jul 2021 → Nov 2024 —
Repare Therapeutics
Terminated
No outcome recorded
Phase 1/2
NCT04655183 Dec 2020 → Sep 2023 breast cancer EMD Serono Research & Development Institute, Inc.
Withdrawn
No outcome recorded
Phase 1/2
NCT04194554 Nov 2020 → May 2027 expected prostate cancer University of Michigan Rogel Cancer Center
Active not recruiting
No outcome recorded
Phase 1/2
NCT03425201 Oct 2019 → Jul 2024 urothelial carcinoma CRIS Cancer Foundation
Completed
No outcome recorded
Phase 1/2
NCT04037254 Oct 2019 → Jul 2024 prostate adenocarcinoma NRG Oncology
Completed
No outcome recorded
Phase 1/2
NCT03368729 Sep 2019 → Nov 2027 expected HER2 positive breast carcinoma University of Alabama at Birmingham
Active not recruiting
No outcome recorded
Phase 1/2
NCT03644342 Jul 2019 → Apr 2022 cervical carcinoma Michelle S Ludwig
Terminated
No outcome recorded
Phase 1/2
NCT03869190 Jun 2019 → Oct 2025 urinary bladder cancer , urothelial carcinoma Hoffmann-La Roche
Completed
No outcome recorded
Phase 1/2
NCT03830918 Mar 2019 → Jan 2027 expected small cell lung carcinoma Jonsson Comprehensive Cancer Center
Active not recruiting
No outcome recorded
Phase 1/2
NCT03404960 Jan 2018 → Apr 2022 pancreatic adenocarcinoma University of Pennsylvania
Completed
No outcome recorded
Phase 1/2
NCT02657889 Apr 2016 → May 2018 fallopian tube cancer , ovarian cancer , peritoneum cancer , triple-negative breast carcinoma Tesaro, Inc.
Completed
No outcome recorded
Phase 1/2
NCT02354131 Feb 2015 → Nov 2018 ovarian cancer Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Completed
No outcome recorded
Show 12 more trials Phase 2 102 trials
Phase 2
NCT06392841 Oct 2025 → Jan 2028 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , CHEK2-related cancer predisposition , Fanconi anemia complementation group A +2 Qian Qin
Withdrawn
No outcome recorded
Phase 2
NCT06747845 May 2025 → Jun 2028 expected pancreatic adenocarcinoma Abramson Cancer Center at Penn Medicine
Recruiting
No outcome recorded
Phase 2
NCT06527690 Apr 2025 → Sep 2027 castration-resistant prostate carcinoma Latin American Cooperative Oncology Group
Withdrawn
No outcome recorded
Phase 2
NCT06365970 Jan 2025 → Jan 2027 colorectal cancer Ibrahim Halil Sahin
Withdrawn
No outcome recorded
Phase 2
NCT06180356 Dec 2024 → Jan 2028 expected ovarian cancer , ovarian serous tumor MedSIR
Recruiting
No outcome recorded
Phase 2
NCT06433219 Oct 2024 → Jun 2026 overdue ovarian carcinoma EMD Serono Research & Development Institute, Inc.
Active not recruiting
No outcome recorded
Phase 2
NCT06535893 Jul 2024 → Jun 2027 expected breast cancer Nagoya City University
Recruiting
No outcome recorded
Phase 2
NCT05990192 Jun 2024 → Dec 2027 expected ovarian carcinoma Institute of Cancer Research, United Kingdom
Recruiting
No outcome recorded
Phase 2
NCT05689021 Mar 2024 → Jul 2026 overdue castration-resistant prostate carcinoma , prostate adenocarcinoma Mayo Clinic
Active not recruiting
No outcome recorded
Phase 2
NCT06237205 Feb 2024 → Jun 2026 overdue —
Korea University Anam Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT05718323 Dec 2023 → Dec 2026 expected small cell lung carcinoma ETOP IBCSG Partners Foundation
Recruiting
No outcome recorded
Phase 2
NCT05174455 Dec 2023 → Dec 2024 leiomyosarcoma , retroperitoneal sarcoma David Liebner, MD
Withdrawn
No outcome recorded
Phase 2
NCT05126342 Nov 2023 → Nov 2024 fallopian tube cancer , ovarian cancer , peritoneum cancer AGO Research GmbH
Withdrawn
No outcome recorded
Phase 2
NCT06141265 Nov 2023 → Sep 2026 expected female reproductive organ cancer Peking University Cancer Hospital & Institute
Recruiting
No outcome recorded
Phase 2
NCT05870761 Oct 2023 → Sep 2025 overdue endometrial serous adenocarcinoma Casey Cosgrove
Active not recruiting
No outcome recorded
Phase 2
NCT05412706 Sep 2023 colorectal cancer Ospedale Policlinico San Martino
Withdrawn
No outcome recorded
Phase 2
NCT05961124 Aug 2023 → Sep 2025 overdue ovarian serous adenocarcinoma Sunnybrook Health Sciences Centre
Recruiting
No outcome recorded
Phase 2
NCT06145308 Aug 2023 → Jul 2028 expected salivary gland carcinoma Peking Union Medical College
Recruiting
No outcome recorded
Phase 2
NCT05601440 Jun 2023 → Dec 2027 expected female breast carcinoma Canadian Cancer Trials Group
Recruiting
No outcome recorded
Phase 2
NCT05700721 Jun 2023 → Dec 2029 expected metastatic malignant neoplasm in the brain M.D. Anderson Cancer Center
Recruiting
No outcome recorded
Phase 2
NCT05065021 Feb 2023 → Jun 2025 endometrioid adenocarcinoma , fallopian tube cancer , ovarian cancer , primary peritoneal carcinoma +1 University Health Network, Toronto
Unknown
No outcome recorded
Phase 2
NCT05523440 Feb 2023 → Jan 2025 endometrial carcinoma , ovarian carcinoma University of Oklahoma
Terminated
No outcome recorded
Phase 2
NCT05526989 Dec 2022 → Nov 2026 expected penile carcinoma H. Lee Moffitt Cancer Center and Research Institute
Recruiting
No outcome recorded
Phase 2
NCT05442749 Oct 2022 → Aug 2024 malignant pancreatic neoplasm Centre Leon Berard
Terminated
No outcome recorded
Phase 2
NCT05461690 Sep 2022 → Dec 2024 triple-negative breast carcinoma Zhejiang Cancer Hospital
Unknown
No outcome recorded
Phase 2
NCT05515575 Aug 2022 → Aug 2026 overdue soft tissue sarcoma Memorial Sloan Kettering Cancer Center
Active not recruiting
No outcome recorded
Phase 2
NCT05335993 Jul 2022 → Dec 2026 expected fallopian tube cancer , ovarian adenocarcinoma , peritoneum cancer CanariaBio Inc.
Active not recruiting
No outcome recorded
Phase 2
NCT05455424 Jul 2022 → Jan 2025 malignant mesothelioma University Hospital Southampton NHS Foundation Trust
Completed
No outcome recorded
Phase 2
NCT05297864 Jun 2022 → Nov 2023 astrocytoma (excluding glioblastoma) , glioblastoma , oligodendroglioma University of Oklahoma
Terminated
No outcome recorded
Phase 2
NCT05385068 Jun 2022 → Mar 2024 malignant epithelial tumor of ovary Peking Union Medical College Hospital
Unknown
No outcome recorded
Phase 2
NCT05162196 Jun 2022 → Jun 2024 small cell lung carcinoma Wuhan University
Unknown
No outcome recorded
Phase 2
NCT05232006 May 2022 → Sep 2024 overdue PALB2-related cancer predisposition Assistance Publique - Hôpitaux de Paris
Not yet recruiting
No outcome recorded
Phase 2
NCT06964165 Apr 2022 → Jun 2024 ovarian neoplasm Tesaro, Inc.
Terminated
No outcome recorded
Phase 2
NCT04992013 Apr 2022 → Dec 2026 expected central nervous system cancer , metastatic malignant neoplasm Massachusetts General Hospital
Active not recruiting
No outcome recorded
Phase 2
NCT05311579 Mar 2022 → Mar 2023 ovarian carcinoma Lei Li
Unknown
No outcome recorded
Phase 2
NCT05169437 Mar 2022 → Aug 2024 breast neoplasm , endometrial cancer , esophageal cancer , head and neck cancer +6 Tempus AI
Terminated
No outcome recorded
Phase 2
NCT05183984 Feb 2022 → Feb 2027 expected ovarian cancer ARCAGY/ GINECO GROUP
Recruiting
No outcome recorded
Phase 2
NCT05130515 Dec 2021 → Jan 2023 carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Completed
No outcome recorded
Phase 2
NCT04983745 Nov 2021 → Aug 2024 neoplastic disease or syndrome West Cancer Center
Unknown
No outcome recorded
Phase 2
NCT04895046 Oct 2021 → Sep 2022 cholangiocarcinoma , metastatic malignant neoplasm Walid Shaib, MD
Withdrawn
No outcome recorded
Phase 2
NCT05162872 Aug 2021 → Jun 2023 nasopharyngeal carcinoma Sun Yat-sen University
Unknown
No outcome recorded
Phase 2
NCT04947254 Aug 2021 → Jun 2028 expected prostate carcinoma M.D. Anderson Cancer Center
Recruiting
No outcome recorded
Phase 2
NCT04837209 Jul 2021 → Feb 2027 expected triple-negative breast carcinoma Massachusetts General Hospital
Active not recruiting
No outcome recorded
Phase 2
NCT04734665 Jul 2021 → Mar 2023 —
Yonsei University
Unknown
No outcome recorded
Phase 2
NCT04885413 Jul 2021 → Aug 2022 endometrium adenocarcinoma Sun Yat-sen University
Unknown
No outcome recorded
Phase 2
NCT04716686 Jun 2021 → Dec 2025 overdue endometrial carcinoma , serous neoplasm Shandong University
Recruiting
No outcome recorded
Phase 2
NCT04641247 Apr 2021 → Dec 2026 expected breast neoplasm , ovarian neoplasm GlaxoSmithKline
Recruiting
No outcome recorded
Phase 2
NCT04779151 Apr 2021 → Feb 2025 biliary tract cancer , clear cell renal carcinoma , gastric adenocarcinoma , gastroesophageal adenocarcinoma +3 Gustave Roussy, Cancer Campus, Grand Paris
Terminated
No outcome recorded
Phase 2
NCT04817956 Apr 2021 → Mar 2040 expected metastatic malignant neoplasm Oslo University Hospital
Recruiting
No outcome recorded
Phase 2
NCT04681469 Feb 2021 → Jun 2023 overdue head and neck squamous cell carcinoma Gruppo Oncologico del Nord-Ovest
Recruiting
No outcome recorded
Phase 2
NCT04701307 Feb 2021 → Apr 2027 expected small cell lung carcinoma M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 2
NCT04507841 Jan 2021 → Sep 2023 overdue ovarian cancer Tongji Hospital
Active not recruiting
No outcome recorded
Phase 2
NCT04715620 Jan 2021 → Jan 2022 glioblastoma Tianjin Huanhu Hospital
Unknown
No outcome recorded
Phase 2
NCT04592237 Dec 2020 → Dec 2027 expected castration-resistant prostate carcinoma , metastatic prostate carcinoma , prostate small cell carcinoma M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 2
NCT04493060 Dec 2020 → Dec 2023 pancreatic ductal adenocarcinoma Mayo Clinic
Completed
No outcome recorded
Phase 2
NCT04940637 Dec 2020 → Jun 2024 lung cancer , mesothelioma University of Turin, Italy
Unknown
No outcome recorded
Phase 2
NCT04584255 Dec 2020 → Jul 2025 overdue BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , Her2-receptor negative breast cancer , PALB2-related cancer predisposition +1 Dana-Farber Cancer Institute
Active not recruiting
No outcome recorded
Phase 2
NCT04556071 Nov 2020 → Mar 2022 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , endocrine gland neoplasm , fallopian tube neoplasm +1 Xiaoxiang Chen
Unknown
No outcome recorded
Phase 2
NCT04313504 Nov 2020 → Jun 2025 head and neck cancer Trisha Wise-Draper
Completed
No outcome recorded
Phase 2
NCT04185831 Oct 2020 → Jan 2024 overdue cancer Uppsala University Hospital
Active not recruiting
No outcome recorded
Phase 2
NCT04288687 Oct 2020 → Feb 2024 prostate adenocarcinoma Abramson Cancer Center at Penn Medicine
Completed
No outcome recorded
Phase 2
NCT04508803 Sep 2020 → Aug 2022 —
Fudan University
Completed
No outcome recorded
Phase 2
NCT04341181 Aug 2020 → Apr 2029 expected cancer Ulrik Lassen
Recruiting
No outcome recorded
Phase 2
NCT04423185 Aug 2020 → Jul 2026 overdue —
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
No outcome recorded
Phase 2
NCT04392102 Aug 2020 → Apr 2021 ovarian cancer Zai Lab (Shanghai) Co., Ltd.
Completed
No outcome recorded
Phase 2
NCT04409002 Jul 2020 → Jan 2022 malignant pancreatic neoplasm Massachusetts General Hospital
Completed
No outcome recorded
Phase 2
NCT04240106 Jun 2020 → Nov 2022 breast carcinoma MedSIR
Completed
No outcome recorded
Phase 2
NCT04376073 May 2020 → Dec 2021 refractory malignant neoplasm Jihong Liu
Unknown
No outcome recorded
Phase 2
NCT04217798 May 2020 → Mar 2022 ovarian carcinoma Peking Union Medical College Hospital
Unknown
No outcome recorded
Phase 2
NCT04395612 May 2020 → Apr 2022 cervical cancer Chongqing University Cancer Hospital
Unknown
No outcome recorded
Phase 2
NCT04284852 May 2020 → Oct 2023 ovarian cancer The University of Hong Kong
Completed
No outcome recorded
Phase 2
NCT04068753 Feb 2020 → Dec 2026 expected cervical carcinoma University of Oklahoma
Active not recruiting
No outcome recorded
Phase 2
NCT04030559 Feb 2020 → Jan 2024 ATM-related cancer predisposition , BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , CHEK2-related cancer predisposition +6 University of California, Davis
Terminated
No outcome recorded
Phase 2
NCT04080284 Dec 2019 → Jan 2025 endometrial carcinoma , endometrial serous adenocarcinoma Northwell Health
Completed
No outcome recorded
Phase 2
NCT04221503 Dec 2019 → Jan 2026 overdue glioblastoma Abramson Cancer Center at Penn Medicine
Active not recruiting
No outcome recorded
Phase 2
NCT03891576 Nov 2019 → Aug 2024 fallopian tube cancer , ovarian cancer , primary peritoneal carcinoma Mario Negri Institute for Pharmacological Research
Terminated
No outcome recorded
Phase 2
NCT03983226 Oct 2019 → Jun 2025 overdue fallopian tube cancer , ovarian carcinoma , primary peritoneal carcinoma Shanghai Gynecologic Oncology Group
Recruiting
No outcome recorded
Phase 2
NCT03983993 Oct 2019 → May 2023 overdue colorectal carcinoma Emory University
Active not recruiting
No outcome recorded
Phase 2
NCT03955471 Oct 2019 → Aug 2021 ovarian neoplasm Tesaro, Inc.
Terminated
No outcome recorded
Phase 2
NCT03945084 Aug 2019 → Sep 2021 urothelial carcinoma University of Turin, Italy
Completed
No outcome recorded
Phase 2
NCT03840967 Jul 2019 → Nov 2022 adenocarcinoma , esophageal cancer , gastric cancer Shadia Jalal, MD
Terminated
No outcome recorded
Phase 2
NCT03925350 Mar 2019 → Feb 2022 metastatic melanoma California Pacific Medical Center Research Institute
Unknown
No outcome recorded
Phase 2
NCT03654833 Jan 2019 → Oct 2023 malignant mesothelioma University of Leicester
Unknown
No outcome recorded
Phase 2
NCT03553004 Jan 2019 → Apr 2023 malignant pancreatic neoplasm University of Kansas Medical Center
Unknown
No outcome recorded
Phase 2
NCT03759587 Dec 2018 → Mar 2019 fallopian tube cancer , ovarian cancer , primary peritoneal carcinoma Takeda
Completed
No outcome recorded
Phase 2
NCT03759600 Dec 2018 → Dec 2022 fallopian tube cancer , ovarian cancer , primary peritoneal carcinoma Takeda
Completed
No outcome recorded
Phase 2
NCT03783949 Nov 2018 → Sep 2023 fallopian tube cancer , ovarian cancer , primary peritoneal carcinoma Universitaire Ziekenhuizen KU Leuven
Completed
No outcome recorded
Phase 2
NCT05751629 Nov 2018 → Apr 2022 ovarian neoplasm Tesaro, Inc.
Completed
No outcome recorded
Phase 2
NCT03574779 Nov 2018 → Jun 2024 ovarian neoplasm Tesaro, Inc.
Completed
No outcome recorded
Phase 2
NCT03601923 Aug 2018 → Dec 2025 malignant pancreatic neoplasm Dana-Farber Cancer Institute
Completed
No outcome recorded
Phase 2
NCT03207347 Aug 2018 → Aug 2022 cholangiocarcinoma , mesothelioma , renal cell carcinoma , uveal melanoma University of Florida
Completed
No outcome recorded
Phase 2
NCT02826512 May 2018 → Jul 2022 breast cancer The Netherlands Cancer Institute
Terminated
No outcome recorded
Phase 2
NCT03431350 Mar 2018 → Aug 2021 overdue castration-resistant prostate carcinoma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 2
NCT03326193 Dec 2017 → Dec 2020 ovarian neoplasm Tesaro, Inc.
Completed
No outcome recorded
Phase 2
NCT03088059 Nov 2017 → Jun 2025 head and neck squamous cell carcinoma European Organisation for Research and Treatment of Cancer - EORTC
Unknown
No outcome recorded
Phase 2
NCT03016338 Nov 2017 → Jan 2021 overdue endometrial cancer University Health Network, Toronto
Active not recruiting
No outcome recorded
Phase 2
NCT03308942 Sep 2017 → May 2020 neoplasm Tesaro, Inc.
Completed
No outcome recorded
Phase 2
NCT02854436 Aug 2016 → Jan 2021 prostate neoplasm Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 2
NCT02925234 Aug 2016 → Sep 2027 expected cancer The Netherlands Cancer Institute
Recruiting
No outcome recorded
Phase 2
NCT02354586 Mar 2015 → Feb 2018 ovarian cancer Tesaro, Inc.
Completed
No outcome recorded
Phase 2
NCT01244009 Dec 2010 → Aug 2013 mantle cell lymphoma Tesaro, Inc.
Withdrawn
No outcome recorded
Phase 2
NCT01042379 Mar 2010 → Dec 2030 expected HER2 positive breast carcinoma , angiosarcoma , female breast carcinoma , hormone receptor-positive breast cancer +1 QuantumLeap Healthcare Collaborative
Recruiting
No outcome recorded
Show 92 more trials Phase 2/3 2 trials
Phase 2/3
NCT04159155 Nov 2020 → May 2025 endometrial carcinoma , serous neoplasm University Health Network, Toronto
Terminated
No outcome recorded
Phase 2/3
NCT03651206 Jul 2020 → Jun 2027 expected ovarian carcinosarcoma , uterine carcinosarcoma ARCAGY/ GINECO GROUP
Recruiting
No outcome recorded
Phase 3 16 trials
Phase 3
NCT05615818 Jul 2024 → Jun 2027 expected biliary tract neoplasm UNICANCER
Recruiting
No outcome recorded
Phase 3
NCT06388733 Jun 2024 → Dec 2027 expected glioblastoma , primary brain neoplasm Ivy Brain Tumor Center
Active not recruiting
No outcome recorded
Phase 3
NCT04915755 Jun 2021 → Jun 2024 overdue breast neoplasm GlaxoSmithKline
Active not recruiting
No outcome recorded
Phase 3
NCT04679064 Dec 2020 → Jan 2025 ovarian cancer Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Unknown
No outcome recorded
Phase 3
NCT04475939 Oct 2020 → Feb 2025 non-small cell lung carcinoma GlaxoSmithKline
Completed
No outcome recorded
Phase 3
NCT04497844 Sep 2020 → Jan 2025 overdue metastatic prostate carcinoma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 3
NCT03806049 Dec 2019 → Dec 2022 ovarian cancer Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Withdrawn
No outcome recorded
Phase 3
NCT03768063 Feb 2019 → Jul 2028 expected cancer Hoffmann-La Roche
Active not recruiting
No outcome recorded
Phase 3
NCT03903835 Feb 2019 → Dec 2026 expected castration-resistant prostate carcinoma , metastatic prostate carcinoma Karolinska Institutet
Recruiting
No outcome recorded
Phase 3
NCT03748641 Jan 2019 → Oct 2021 overdue castration-resistant prostate carcinoma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 3
NCT03602859 Oct 2018 → Oct 2024 overdue female reproductive organ cancer , ovarian neoplasm Tesaro, Inc.
Active not recruiting
No outcome recorded
Phase 3
NCT03516084 Aug 2018 → Feb 2020 small cell lung carcinoma Zai Lab (Shanghai) Co., Ltd.
Terminated
No outcome recorded
Phase 3
NCT03709316 Jun 2018 → Jan 2022 ovarian cancer Zai Lab (Shanghai) Co., Ltd.
Unknown
No outcome recorded
Phase 3
NCT03705156 Jun 2017 → Feb 2020 —
Zai Lab (Shanghai) Co., Ltd.
Unknown
No outcome recorded
Phase 3
NCT02655016 Jul 2016 → May 2019 overdue ovarian neoplasm Tesaro, Inc.
Active not recruiting
No outcome recorded
Phase 3
NCT01905592 Feb 2014 → May 2018 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , Her2-receptor negative breast cancer , ovarian neoplasm Tesaro, Inc.
Terminated
No outcome recorded
Show 6 more trials Phase 4 5 trials
Phase 4
NCT06412120 Jun 2026 → Jun 2029 expected ovarian cancer University of Miami
Recruiting
No outcome recorded
Phase 4
NCT06887933 Apr 2025 → Mar 2026 overdue ovarian neoplasm GlaxoSmithKline
Not yet recruiting
No outcome recorded
Phase 4
NCT05187208 Jan 2022 → Dec 2025 ovarian carcinoma , uterine adnexa cancer Seoul National University Hospital
Unknown
No outcome recorded
Phase 4
NCT04861181 May 2021 → Apr 2025 —
Hospices Civils de Lyon
Terminated
No outcome recorded
Phase 4
NCT03752216 Apr 2019 → Aug 2021 ovarian cancer ARCAGY/ GINECO GROUP
Completed
No outcome recorded
Phase not stated 2 trials
— NCT03025867 — ovarian cancer Tesaro, Inc.
Approved for marketing
No outcome recorded
— NCT05401214 — prostate carcinoma Janssen Research & Development, LLC
Approved for marketing
No outcome recorded